For ten years, the Valneva laboratory has tried to develop a vaccine against Lyme disease, a condition that spreads exponentially each year. Research that could soon bear fruit …
First conclusive test phases
In an interview with France Info Last Saturday, Franck Grimaud, CEO of Valneva, announced that he hoped to offer this vaccine by 2025. “The first tests aimed at guaranteeing its harmlessness in humans have already taken place. We are in the process of taking a second step, which is to test the best volume / efficacy ratio”, he clarified. To do this, the laboratory will observe, in 2022, the reactions of nearly 16,000 patients: half will not be vaccinated while the other will be administered the famous vaccine.
A health emergency
In Europe, Lyme disease affects nearly 250,000 people each year *. To curb the growing development of this infectious pathology, the director general of the Valneva laboratory insists on the importance of “monitoring of walks”. In fact, since the arrival of fine weather, many of us have taken long walks in the forest or in the parks. Praised by the French, these green spaces are also the favorite playground for insects, especially ticks. Hidden in tall grass and brush, these arachnids can carry the bacteria. “borrelia“, at the root of Lyme disease. This pathology can, if not diagnosed in time, which is often the case due to screening tests deemed unreliable. cause facial paralysis or flu-like symptoms. The nerves and joints can be seriously damaged.
It is therefore necessary to be extra vigilant during walks in the forest, in particular. If you notice a red spot on your skin, it is imperative to consult your doctor. Once the diagnosis is made, an antibiotic may be prescribed to stop the infection.
* Source: Valneva Laboratory
Source: femmeactuelle.fr
